SPRX-105 Drug Patent Profile
✉ Email this page to a colleague
Which patents cover Sprx-105, and when can generic versions of Sprx-105 launch?
Sprx-105 is a drug marketed by Numark and is included in one NDA.
The generic ingredient in SPRX-105 is phendimetrazine tartrate. There are five drug master file entries for this compound. Twelve suppliers are listed for this compound. Additional details are available on the phendimetrazine tartrate profile page.
DrugPatentWatch® Litigation and Generic Entry Outlook for Sprx-105
A generic version of SPRX-105 was approved as phendimetrazine tartrate by VIRTUS on December 31st, 1969.
AI Research Assistant
Questions you can ask:
- What is the 5 year forecast for SPRX-105?
- What are the global sales for SPRX-105?
- What is Average Wholesale Price for SPRX-105?
Summary for SPRX-105
| US Patents: | 0 |
| Applicants: | 1 |
| NDAs: | 1 |
| Raw Ingredient (Bulk) Api Vendors: | 21 |
| Patent Applications: | 1,902 |
| DailyMed Link: | SPRX-105 at DailyMed |
US Patents and Regulatory Information for SPRX-105
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Numark | SPRX-105 | phendimetrazine tartrate | CAPSULE, EXTENDED RELEASE;ORAL | 088024-001 | Dec 22, 1982 | DISCN | No | No | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | ||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
